Pathophysiology of Growth Hormone Signaling Resistance

Abstract

Growth hormone (GH) signaling resistance represents a significant clinical challenge, contributing to a spectrum of disorders ranging from growth failure in children to metabolic dysfunction in adults. This article reviews the underlying pathophysiology, epidemiology, risk factors, clinical manifestations, diagnostic considerations, and current as well as emerging therapeutic strategies for GH signaling resistance. Emphasis is placed on mechanistic insights, clinical relevance, and practical management approaches in alignment with recent evidence and guidelines.

Introduction

Growth hormone plays an indispensable role in regulating somatic growth, metabolism, and tissue repair. Resistance to GH signaling encompassing states such as GH insensitivity and partial resistance impairs these physiological processes, with profound clinical implications. A mechanistic understanding of GH resistance is essential for clinicians, particularly given the expanding spectrum of etiologies and the evolving landscape of targeted therapies. This review synthesizes recent advances and provides a practical framework for the evaluation and management of GH signaling resistance.

Epidemiology / Disease Burden

GH signaling resistance, while rare, is increasingly recognized due to advances in molecular diagnostics. Laron syndrome, the archetypal form of congenital GH insensitivity, has an estimated prevalence of 1 in 1,000,000 worldwide, with higher incidence in specific populations such as Ecuadorian and Israeli cohorts. Acquired GH resistance, often secondary to chronic illness, obesity, aging, or inflammatory conditions, is more prevalent and contributes significantly to morbidity in both pediatric and adult populations. The disease burden is amplified by the metabolic, cardiovascular, and psychosocial complications associated with impaired GH action.

Pathophysiology

GH signaling resistance arises from defects at multiple levels of the GH-IGF-1 axis. Classically, pathogenic variants in the GH receptor (GHR) gene result in impaired ligand binding or receptor signal transduction, as seen in Laron syndrome. Post-receptor defects including mutations in the Janus kinase 2 (JAK2), signal transducer and activator of transcription 5b (STAT5b), and downstream IGF-1 gene also contribute. Additionally, acquired resistance is mediated by increased levels of circulating GH binding proteins, inflammatory cytokines (notably IL-6 and TNF-α), and suppressor of cytokine signaling (SOCS) proteins, which attenuate GH signaling. Obesity and chronic systemic inflammation further disrupt the GH-IGF-1 axis by altering receptor sensitivity and post-receptor signaling pathways. These mechanisms collectively result in reduced IGF-1 bioactivity despite normal or elevated GH levels, with downstream effects on growth, metabolism, and tissue homeostasis.

Risk Factors

Risk factors for GH signaling resistance can be broadly categorized as genetic or acquired. Genetic risk factors include mutations in the GHR, STAT5b, IGF1, or IGF1R genes, often inherited in an autosomal recessive pattern. Acquired risk factors encompass chronic inflammatory diseases (e.g., juvenile idiopathic arthritis, Crohn’s disease), obesity, type 2 diabetes, malnutrition, chronic kidney disease, and prolonged exposure to exogenous glucocorticoids. Aging is also associated with a physiological decline in GH responsiveness. Early identification of at-risk individuals is critical for timely intervention and mitigation of long-term sequelae.

Clinical Features

The clinical phenotype of GH signaling resistance varies with the underlying etiology and severity. In congenital forms such as Laron syndrome, hallmark features include severe postnatal growth failure, markedly short stature, prominent forehead, midfacial hypoplasia, delayed skeletal maturation, and hypoglycemia. In contrast, acquired resistance typically presents with subtle growth deceleration, increased adiposity, decreased muscle mass, impaired quality of life, and increased cardiovascular risk. Adults may exhibit dyslipidemia, insulin resistance, osteoporosis, and accelerated atherosclerosis. Recognition of these features in the appropriate clinical context should prompt thorough evaluation of the GH-IGF-1 axis.

Diagnosis

Diagnosis of GH signaling resistance hinges on a combination of clinical, biochemical, and molecular assessments. Initial evaluation includes measurement of serum IGF-1 and IGFBP-3 levels, followed by stimulation tests to assess GH secretion. In classical GH insensitivity, IGF-1 levels are low despite normal or elevated GH concentrations. Genetic testing for mutations in GHR and related signaling pathways is essential for definitive diagnosis, particularly in congenital cases. Ancillary investigations such as bone age assessment, metabolic panel, and imaging may aid in evaluating comorbidities and guiding management.

Treatment & Management

Therapeutic strategies for GH signaling resistance are tailored to the underlying defect. Recombinant IGF-1 (mecasermin) is the cornerstone of therapy for congenital GH insensitivity and selected post-receptor defects. Dosing and monitoring must be individualized to optimize growth response while minimizing hypoglycemia risk. In acquired resistance, management focuses on treating underlying conditions (e.g., optimizing glycemic control, reducing inflammation), weight loss in obesity, and addressing associated metabolic derangements. Multidisciplinary care including endocrinology, nutrition, and psychology is vital for comprehensive management, particularly in complex cases.

Recent Advances / Emerging Therapies

Recent advances in the understanding of GH signaling resistance have catalyzed the development of novel therapeutic approaches. These include long-acting IGF-1 analogs, combination therapy with IGF-1/IGFBP-3 complexes, and targeted inhibitors of SOCS proteins to enhance GH sensitivity. Gene therapy and molecular chaperones represent promising avenues for correcting specific genetic defects. Additionally, precision medicine strategies guided by molecular profiling are being explored to optimize therapy for individual patients. Ongoing clinical trials are expected to further refine these approaches and expand the therapeutic armamentarium.

Guideline Recommendations

Current clinical guidelines recommend early identification and molecular characterization of GH signaling resistance to guide targeted therapy. The Pediatric Endocrine Society and other expert panels advocate for the use of recombinant IGF-1 in confirmed cases of congenital GH insensitivity, with close monitoring for efficacy and safety. Multidisciplinary management and patient education are emphasized, particularly regarding the risk of hypoglycemia and the importance of adherence. In acquired forms, guidelines highlight the necessity of addressing underlying comorbidities and optimizing overall metabolic health. Regular follow-up and individualized treatment adjustments are essential for achieving optimal outcomes.

Conclusion

GH signaling resistance encompasses a heterogeneous group of disorders with significant clinical and metabolic consequences. Advances in molecular genetics and targeted therapeutics have transformed the diagnostic and therapeutic landscape, enabling more precise and effective management. Ongoing research into the molecular mechanisms of resistance and the development of novel agents holds promise for further improving patient outcomes. Clinicians must maintain a high index of suspicion, employ a systematic diagnostic approach, and collaborate within multidisciplinary teams to deliver optimal care for affected individuals.